Gregory C. Critchfield, MD, MS
Chairman, President, and CEO
“The work that Sera Prognostics is doing is groundbreaking and game-changing. It was so important to me to be a part of this effort that I left retirement to help Sera develop technologies to improve outcomes for mothers and their babies.” Dr. Critchfield was appointed as Sera’s CEO in November 2011. Before joining Sera, Dr. Critchfield was president of Myriad Genetics Laboratories from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Myriad, he served as senior vice president/chief medical and science officer at Corning Clinical Laboratories/Quest Diagnostics. Dr. Critchfield has served on the boards of Saladax Biomedical, BioTrove, Biocius, Integrated Diagnostics, Nodality, Metamark Genetics, Lantos Technologies, Epic Sciences, and Condor Therapeutics. He holds a B.S. in Microbiology from BYU, an M.D. from the University of Utah College of Medicine, and an M.S. in Biophysical Sciences from the University of Minnesota.
Nadia F. Altomare
Chief Commercial Officer
"I am inspired by the innovation of Sera’s technology and I believe that we can lead the way to decrease the frequency and severity of preterm birth, and importantly, advocate for a new standard to detect premature birth early." Nadia Altomare has more than 20 years of women’s healthcare experience and an extensive knowledge in developing and implementing strategic plans to drive commercial growth in the life sciences, biotechnology, and diagnostic industries. Ms. Altomare has held senior management positions in single and multi-product/service environments spanning from entrepreneurial to Fortune 500 companies. Ms. Altomare served as chief executive officer of an early detection of cancer diagnostics company, Abcodia Limited, where she shaped the global commercial, regulatory and fundraising strategies for the business. In addition, she served as vice president and general manager of the DNA analysis business at ThermoFisher Scientific (formerly Life Technologies) and also held leadership roles at PerkinElmer, including as the vice president & general manager of the cytogenetic DNA testing and as vice president of commercial operations, where she integrated the ViaCord acquisition into the broader diagnostic unit.
Jay Boniface, PHD
Chief Scientific Officer
"At Sera, I can draw upon my training in protein biochemistry, proteomics, reproductive endocrinology, and biomarker discovery to enable product development in unmet areas of women’s health. I can do so surrounded by employees, leadership, and investors that repeatedly ask: 'what is best for the patient' and are committed to solving challenging health problems with high standards of ethics." Dr. Boniface previously served as scientist and program director for a number of biotechnology companies focused on protein discovery and small molecule and immunotherapeutic drug development including Myrexis, Myriad Genetics, Prolexys Pharmaceuticals, and Eos Biotechnology. Dr. Boniface earned his Ph.D. in biochemistry at Albany Medical College and was a postdoctoral scholar in molecular immunology at Stanford University.
Jay M. Moyes
Chief Financial Officer
“Sera has achieved remarkable progress in building a world-class approach to address the immense burden of premature birth. I am excited to join the talented Sera team and help accelerate the company’s progress.” Jay Moyes has served in C-level executive and board positions of private and public companies. He currently serves as Director of Achieve Life Sciences (NASDAQ: ACHV), BioCardia (BCDA) and Puma Biotechnologies (PBYI). He has previously served on boards of the Predictive Technology Group (PRED); Osiris Therapeutics (OSIR); and Integrated Diagnostics (acquired by Biodesix), and as Chief Financial Officer and Director of Amedica Corporation (now SINTX Technologies), managing the company’s IPO and listing on NASDAQ; and as Chief Financial Officer at XDx (now CareDx – CDNA). Jay led the finance function at Myriad Genetics (MYGN), serving until 2007 as Chief Financial Officer during Myriad’s rapid growth trajectory to become one of the world’s most highly profitable molecular diagnostics companies. During that time, Moyes spearheaded the efforts in raising more than $500 million in public and private financings. Mr. Moyes served as Chief Financial Officer of Genmark until 1993, a privately held genetics company. Mr. Moyes held various positions with the accounting firm KPMG from 1979 to 1991. Mr. Moyes holds a Master of Business Administration from the University of Utah, a Bachelor of Arts in economics from Weber State University and is formerly a Certified Public Accountant.
Douglas Fisher, MD
Chief Business Officer
“I have been involved with a number of women’s health companies, but none of them will impact patients’ lives more than Sera. Developing tests that predict pregnancy complications will enable improved disease management and benefit thousands, if not millions, of women and their babies.” Dr. Fisher is a former partner of InterWest Partners, LLC, and served on Sera’s Board of Directors since the company’s Series A funding in November 2011. He joined Sera as its business and strategy development executive in January 2015 and continues to serve as an Executive-in-Residence at InterWest Partners. Dr. Fisher has focused on biopharmaceutical, diagnostic, and medical device investments throughout his career, working in venture capital, consulting, and pharmaceutical industries. He received his M.D. and M.B.A. from the School of Medicine and the Wharton School, respectively, at the University of Pennsylvania.
Thomas J Garite, M.D.
Vice President of Clinical Sciences
“I am very pleased to take part in a vision that puts the well-being of mothers and newborns at the forefront, by conducting careful scientific and clinical research to address the challenges of prematurity and other conditions of pregnancy,” said Dr. Garite. “Preterm birth now exceeds 10% in the US and is a major cause of death and impairment of newborns. I look forward to providing my scientific experience and medical knowledge to help the company realize clinical and commercialization strategies that effectively address this serious healthcare crisis.” Dr. Garite is a world-renowned and highly respected expert in Obstetrics and Gynecology and Maternal-Fetal Medicine and a recently retired Edward H. Quilligan Professor of Obstetrics and Gynecology at the University of California at Irvine. Dr. Garite served 18 years as this Department’s Chairman, and now holds the title of Professor Emeritus. He is also the past Editor in Chief of the American Journal of Obstetricians and Gynecology and remains Editor Emeritus. He has published more than 200 articles and chapters including over 150 original peer-reviewed journal articles and is the author or co-author of five textbooks. His research has focused on intrapartum and antepartum fetal assessment through fetal heart rate monitoring, prematurity in general, premature rupture of membranes, the infectious etiology of prematurity, and the management of labor. Until recently, Dr. Garite served as Director of Research and Education for Obstetrix, MedNax Medical Group where he directed the only ongoing Collaborative Clinical Research group composed of a consortium of private practices and university Maternal-Fetal medicine groups. Under his leadership, his team published 25 collaborative studies including 10 multicenter collaborative research trials all in high impact obstetric journals during his 18-year tenure with the company. He also currently serves as Chief Clinical Officer for Perigen Inc, a national patient safety company. “Dr. Thomas Garite has tirelessly dedicated his professional energies to building impactful knowledge that has improved the practice of obstetrics,” said Gregory C. Critchfield, MD., MS, Chairman, and CEO. “We are very fortunate to have Dr. Garite join the Sera team. He will provide critical leadership and support in advancing our clinical development efforts that are the basis of achieving Sera’s vision to improve the health of mothers and newborns and thereby improve the economics of health care delivery.”
Robert G. Harrison
Chief Information Officer
“Sera has achieved remarkable progress in its information-rich and data-driven approach to address the immense burden of premature birth,” said Rob Harrison. “Strong data readouts from multiple studies covering analytic validity, clinical validity, and both clinical and health economic outcomes form a solid foundation to enable Sera to play a leading role in addressing the enormous personal, societal and economic consequences of prematurity, and of other adverse pregnancy conditions. I am excited to join the talented Sera team and help build technology platforms that drive the company’s progress.” For more than three decades, Rob Harrison has served in several senior leadership positions of both public and private companies. His most recent appointment has been with Myriad Genetics, Inc. (NASDAQ: MYGN) as Chief Information Office Officer, where he architected the IT infrastructure that enabled Myriad to grow from its first product launch in 1996 with fewer than 100 employees in a single location, to become a leading global precision medicine company, with multiple products, more than 2,700 employees and deploying testing facilities and services in three continents. Rob successfully directed the IT integration of strategic acquisitions of four companies, simultaneously facilitating international business expansion over the past decade in the company’s growth. Serving as a long-standing board member of the Utah Technology Council, Mr. Harrison remains an active member of the Association for Information Management (AIM) Utah CIO Council, and is also a respected community leader committed to charitable causes that benefit the well-being of women.
Benjamin G. Jackson
“Sera has made great strides in building evidence that PreTRM® testing improves the ability to identify pregnancies that are at higher risk of preterm delivery, thereby enabling proactive interventions designed to help address the immense burden of premature birth,” said Ben Jackson. “I am personally energized to join Sera, working with Greg and the rest of the talented Sera team to help drive the company’s progress to improve the lives of mothers and newborns. I believe Sera has great potential to help mitigate the enormous personal, societal and economic consequences of premature births and other adverse pregnancy consequences.” For the last 15 years, Ben has represented Myriad Genetics, Inc., beginning as a law clerk, initially focusing on intellectual property, and ultimately advancing to become General Counsel of a global molecular diagnostics enterprise. Mr. Jackson is viewed as a thought leader who has written and presented extensively in the area of molecular diagnostics intellectual property, while also possessing broad experience in a wide range of legal matters, including patent and commercial litigation, M&A transactions, interactions with government and private payers, corporate legal policies and contracting.